Users will be able to access DeepScribe’s documentation platform through AWS.
Stock.adobe.com
DeepScribe announced that its ambient AI clinical documentation software is available as a purchasing option on Amazon’s AWS Marketplace.1 This includes the entirety of Deepscribe’s platform, including Customization Studio, Clinical Moments, and Real-Time. Healthcare organizations will have the ability to deploy ambient AI that integrates directly with their HER.
In a press release, DeepScribe co-founder and COO said, “Our inclusion in the AWS Marketplace is made possible by our work with AWS as well as the integrity of our enterprise-ready AI clinical documentation solution. The increased accessibility will enable enterprise healthcare organizations to consolidate their cloud spend and more easily deploy DeepScribe to address the critical issue of clinician burnout as it automates clinical documentation, improves efficiency, and allows greater focus on delivering patient care."
In the same press release, Deepscribe’s co-founder and CEO Akilesh Bapu said, “Healthcare systems are moving fast to adopt the AI stack of the future, from ambient AI to clinical decision support. We think it's important to make rolling out this stack as seamless as possible–with this, rolling out DeepScribe is easier than ever, directly through AWS."
In February, Deepscribe announced that it had partnered with Amazon Web Services (AWS) to develop and scale large language models for healthcare. In a press release,2 Deepscribe stated that, as part of this partnership, it would incorporate AWS HealthScribe onto its platform.
In a press release issued at the time, Covenant HealthCare vice president and chief information officer Frank Fear said, “We're extremely excited about the transformative potential DeepScribe's AI technology brings to our health system. DeepScribe is empowering us to alleviate the documentation burden, deliver exceptional patient care, and make good on our commitment to prioritize clinician well-being."
In the same press release, Bapu added, “We are excited to be working with AWS to eliminate the burden of documentation for exponentially more providers and unlock better, more accurate medical reasoning capabilities. AWS generative AI services, paired with our dataset, will allow us to push the boundaries of AI in care delivery.”
According to Deepscribe, it had already processed and labeled more than 3 million clinical conversations on the platform by February. Due to the nature of these conversations, they were de-identified prior to being processed. This data was used to train multiple LLMs and AI programs to be used within the healthcare landscape.
AWS’ chief medical officer, Jared Saul, said in a press release, “Reducing documentation burden is a prime example of how generative AI can be applied to positively impact clinician and patient experiences. We're excited to be supporting DeepScribe's work in scaling adoption of clinical AI and purpose-built LLMs."
FDA Approves Opdivo Plus Yervoy Regimen for MSI-H/dMMR Colorectal Cancer
April 9th 2025Approval of the Opdivo plus Yervoy combination regimen was based on results from the Phase III CheckMate-8HW trial, which was the largest immunotherapy study in patients with previously untreated, unresectable, or metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Trump: 'Major Tariff' on Pharmaceuticals Coming Soon
Published: April 9th 2025 | Updated: April 9th 2025“We’re going to tariff our pharmaceuticals, and once we do that, they are going to come rushing back into our country," President Donald J. Trump said during a Tuesday night dinner in Washington.